CAMBRIDGE, Mass., Jan. 18 /PRNewswire/ -- Cytel, the leading provider of adaptive clinical trial services and software, announced today that its Dr. Jerald Schindler and Dr. Nitin Patel will present case studies and lead discussions at the Center for Business Intelligence (CBI) Dose Finding Clinical Trial conference to be held February 26 - 27 in West Conshohocken, PA. The meeting will focus on the biopharmaceutical industry’s widening application of recently-developed adaptive methods in early-phase dosing clinical studies.
Cytel’s Dr. Schindler and Dr. Patel will be joined by fellow experts from both academia and major biopharmaceuticals, including Merck, Novartis, Millennium, Glaxo Smith Kline, Bristol-Myers Squibb and Johnson & Johnson. The wide array of companies engaged in Bayesian adaptive dose-finding clearly indicates the industry’s belief that these innovative methods provide better data for the dose-selection decisions that are crucial to more efficient and successful confirmatory trials.
As Chairman of the two-day conference Dr. Schindler, President, Cytel Pharmaceutical Research Division, kicks off the day-one agenda with an outline of how utilization of Cytel’s adaptive statistical methodologies and resultant design are particularly well-suited to the all-important dose-finding phase. Dr. Schindler will also discuss the readiness of both the FDA and the EMEA to accept and approve dose finding data.
Dr. Patel, Co-founder, Chairman and CTO, of Cytel, Inc., will discuss an innovative software tool developed jointly with Merck Research Labs that simulates adaptive dose allocation and compares the efficiency of adaptive Bayesian and frequentist methods to traditional designs. This tool effectively identifies for Merck the advantage innovative methods provide when planning their early phase studies.
“Our simulations support the broad conclusion that for the same sample size, the Bayesian method gives a mean squared error that is approximately half that of the traditional design for estimating the mean response at every dose level,” reports Dr. Patel.
Clinical development professionals interested in attending can find complete conference speakers, agenda and registration information at: http://www.cbinet.com/show_conference.cfm?confCode=HB709 or via www.cytel.com
Dr. Schindler and Dr. Patel will be available for interviews during the conference to industry press and analysts. To schedule, please contact:
Michael Weitz Marketing Communications Director mike@cytel.com +1.617.661.2011 About Cytel
Cytel Inc. (www.cytel.com) is the leading provider of clinical trial consulting services and specialized statistical software for the biopharmaceutical, medical device, academic, and research institute markets. Cytel’s innovative trial designs reduce development costs and lead times and facilitate better decisions that increase the probability of clinical trial success. Entering its 20th year, Cytel Inc. is headquartered in Cambridge MA, with software development and statistics outsourcing facilities in Pune, India.
About CBI Research, Inc.
CBI is a privately held, world-class conference company that focuses on producing high-level programs for executive decision-makers who face strategic issues in domestic and international markets. CBI has provided information and networking opportunities for thousands of senior-level executives in various industries. More information at www.cbinet.com
Cytel Inc.
CONTACT: Michael Weitz, Marketing Communications Director of Cytel Inc.,+1-617-661-2011, or mike@cytel.com
Web site: http://www.cytel.com//
